Samtasu Post-marketing General Drug Use-results Survey in Patients With Volume Overload in Heart Failure.

Study Overview
=================
Brief Summary
-----------------
To confirm the safety of tolvaptan sodium phosphate in patients with volume overload in heart failure.

Official Title
-----------------
Samtasu Post-marketing General Drug Use-results Survey in Patients With Volume Overload in Heart Failure.

Conditions
-----------------
Heart Failure

Intervention / Treatment
-----------------
* Drug: Samtasu for I.V. infusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Exclusion Criteria: patients with a known hypersensitivity to Tolvaptan sodium phosphate or Tolvaptan

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Samtasu for I.V. infusion|Drug: 8 mg/vial or 16mg/vial Dosage and Administration: The usual adult dosage of tolvaptan sodium phosphate is 16 mg once daily and intravenously infused over 1 hour.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety information (Adverse Event) | Any untoward medicinal occurrence in a patient or clinical study subject administered a Medicinal Product and which does not necessarily have a causal relationship with this treatment (see Annex Ⅳ, ICH-E2A Guideline). An Adverse Event can therefore be any unfavorable and unintended sign (e.g. abnormal laboratory finding), symptom, or disease temporally associated with the use of a Medicinal Product, whether or not it is considered causally related to the Medicinal Product. | 14 days from the initiation of tolvaptan sodium phosphate treatment | 
| Number of Special Situations | Collecting any Situations related to the use of an Otsuka product which may or may not be associated with an adverse event: Maternal (pregnancy and breastfeeding) or paternal (via semen) exposure; Exposure during breastfeeding; Overdose/Incorrect dosage, misuse, abuse (e.g. patient sharing products); Medication errors (e.g. patient took wrong dose); Lack of therapeutic efficacy (e.g. the product doesn't work); Occupational exposure (e.g.: nurse administering the product is exposed); Cases of suspected transmission of infectious agents; Use of suspected or confirmed falsified product(s) or quality defect of the product(s); Withdrawal reactions; Accidental exposure (e.g.: child takes parent's product); Drug-drug/drug-food interactions; Unintentional use of product in a non-approved population (e.g.: pediatric or geriatric population); Disease progression/exacerbation of existing disease | 14 days from the initiation of tolvaptan sodium phosphate treatment | 
| Number of off-Label Use | Collecting any type of off-Label Use that refers to situations where a product is intentionally used for a medical purpose not in accordance with the authorized product information. Off-label use also includes the intentional use in nonauthorized population categories not indicated in the label. | 14 days from the initiation of tolvaptan sodium phosphate treatment | 
| Incidence of Serious Adverse Event (e.g. resulting in death or life-threatening) | Collecting the number of any adverse drug experience/event occurring at any dose which results in death is life-threatening requires inpatient hospitalization or prolonged of existing hospitalization results in persistent or significant disability or incapacity is a congenital anomaly/birth defect is medically significant. | 14 days from the initiation of tolvaptan sodium phosphate treatment | 
| Incidence of Non-serious Adverse Events (i.e. all Adverse Events that do not meet the definition of a serious Adverse Event) | Collecting the number of non-serious Adverse Events | 14 days from the initiation of tolvaptan sodium phosphate treatment |